TABLE 1.
Characteristics of Study Participants
| Crohn Disease (n = 9) | Ulcerative Colitis (n = 6) | Total Cohort (n = 15) | |
|---|---|---|---|
| Age (y), mean (SD) | 45 (22) | 41 (15) | 44 (19) |
| Female, n (%) | 7 (78) | 4 (67) | 11 (73) |
| IBD duration (y), mean (SD) | 21.4 (15.0) | 15.3 (14.6) | 19.0 (14.6) |
| IBD location | Ileal (n = 4) | Rectum (n = 1) | n/a |
| Colonic (n = 2) | Left side (n = 2) | ||
| Ileocolonic (n = 2) | Pancolitis (n = 3) | ||
| Ileocolonic with perianal disease (n = 1) | |||
| Tobacco use | |||
| Never, n (%) | 5 (56) | 6 (100) | 11 (73) |
| Current, n (%) | 0 (0) | 0 (0) | 0 (0) |
| Former, n (%) | 4 (44) | 0 (0) | 4 (27) |
| IBD medication use | |||
| Mesalamine, n (%) | 2 (22) | 5 (83) | 7 (47) |
| Immunomodulator, n (%) | 2 (22) | 0 (0) | 2 (13) |
| Biologic, n (%) | 6 (67) | 1 (17) | 7 (47) |
| Systemic steroid, n (%) | 1 (11) | 2 (33) | 3 (20) |
| Fecal calprotectin (µg/g), mean (range) | 404 (0–1269) | 376 (25–1177) | 392 (0–1269) |
| C-reactive protein (mg/L), mean (SD) | 7.6 (13.0) | 6.7 (6.9) | 7.3 (10.7) |
n/a, not available.